SYNAPSEN - Étude de Cas 2023-2024
Innovative rare disease treatments
- B2B
About SYNAPSEN - Étude de Cas 2023-2024
French company specializing in neuromuscular disorders, focusing on innovation and patient-centered values Developing a new treatment to launch in France
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1–10 employees
- Headquarters
- Orsay, Île-de-France, France
- Founded
- 2002
- Revenue
- $2.3M – $18.1MTamtam estimate
- Website
- instagram.com
SYNAPSEN - Étude de Cas 2023-2024 at a glance
SYNAPSEN - Étude de Cas 2023-2024 is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Orsay, Île-de-France, France.
SYNAPSEN - Étude de Cas 2023-2024 was founded in 2002.
SYNAPSEN - Étude de Cas 2023-2024 has 1–10 employees.
SYNAPSEN - Étude de Cas 2023-2024's revenue is $2.3M – $18.1M (Tamtam estimate).
Selling to companies like SYNAPSEN - Étude de Cas 2023-2024?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies